Pfizer Overview
Pfizer Inc. is a global biopharmaceutical company with a portfolio across vaccines, oncology, internal medicine, inflammation and immunology, rare disease, anti-infectives, and hospital products. FY2025 revenue was $62.579 billion, and net income was $7.771 billion. Pfizer employed about 75,000 people worldwide as of December 31, 2025. The company trades on the NYSE under PFE and is led by Chairman and CEO Albert Bourla.
How Pfizer Makes Money
Pfizer makes money from patented prescription medicines, vaccines, oncology products, hospital therapies, rare disease products, collaborations, and global commercial distribution. Its economics depend on R&D success, regulatory approvals, patent protection, reimbursement, and lifecycle management.
Pfizer Financials
Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
Competitive Position
Pfizer competes with Merck, Johnson & Johnson, Eli Lilly, AbbVie, Moderna, Sanofi, Novartis, AstraZeneca, Bristol Myers Squibb, and biotechnology companies across vaccines, oncology, immunology, rare disease, and internal medicine. Its challenge is to turn scale into new product growth fast enough to offset exclusivity losses.
